Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
China Pharmaceutical University
InstitutionResearch output, impact & collaborations
China Pharmaceutical University is a research organisation in Nanjing, CN. OpenAlex records 39,318 works and 3,638,220 citations for it. 14,710 researchers list it as their most recent affiliation.
39,318
Works
3,638,220
Citations
14,710
Researchers
56.5
Avg h-index
How has China Pharmaceutical University's publication output changed over time?
ScholarIQpublication output · 2011–2022
Output grew0% over the shown period — from 1 works in 2011 to 1 in 2022.
1
1
1
1
1
3
3
1
20112013201520162017202020212022
Who are the most-cited researchers behind China Pharmaceutical University?
ScholarIQtop researchers by citations
What are the most-cited papers on China Pharmaceutical University?
ScholarIQmost cited works
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, J. Nam, Sofía Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Christopher D. Buckley, Frank Buttgereit, Vivian P. Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan J. Gómez‐Reino, Laure Gossec, J.-E. Gottenberg, Johanna M W Hazes, T. Huizinga, Meghna Jani, Д. Е. Каратеев, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain B. McInnes, Eduardo Mysler, Peter Nash, Karel Pavelká, Gyula Poór, Christophe Richez, Piet L. C. M. van Riel, Andrea Rubbert‐Roth, Kenneth G. Saag, José António Pereira da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Annals of the Rheumatic Diseases. 20175,784 CitationsOPEN ACCESS
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, Gerd R Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B. McInnes, Alexandre Sepriano, Ronald van Vollenhoven, Maarten de Wit, Daniel Aletaha, Martin Aringer, Johan Askling, Alejandro Balsa, Maarten Boers, Alfons A den Broeder, Maya H Buch, Frank Buttgereit, Roberto Caporali, Myrna Cardiel, Diederik De Cock, Cătălin Codreanu, Maurizio Cutolo, Christopher J Edwards, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques‐Eric Gottenberg, Merete Lund Hetland, T. Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller‐Ladner, Eduardo Mysler, José António Pereira da Silva, Gyula Poór, Janet Pope, Andrea Rubbert‐Roth, Adeline Ruyssen‐Witrand, Kenneth G. Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée van der Heijde
Annals of the Rheumatic Diseases. 20202,781 CitationsOPEN ACCESS
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Josef S Smolen, Robert Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher J Edwards, Kimme L Hyrich, Janet Pope, Savia de Souza, Tanja Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin Winthrop, Alejandro Balsa, Joan M. Bathon, Maya H Buch, Gerd R Burmester, Frank Buttgereit, Myrna Cardiel, Katerina Chatzidionysiou, Cătălin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques‐Eric Gottenberg, Espen A. Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo Mysler, Peter Nash, Gyula Poór, Gorica Ristić, Felice Rivellese, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Nikolay Stoilov, Anja Strangfeld, Annette H M van der Helm–van Mil, Elsa van Duuren, T. P. M. Vliet Vlieland, René Westhovens, Désirée van der Heijde
Annals of the Rheumatic Diseases. 20221,851 CitationsOPEN ACCESS
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators
Journal of Clinical Oncology. 20201,190 Citations
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Rui‐Hua Xu, Zhehai Wang, Qiong Wang, Xuenong Ouyang, Yan Yang, Yi Ba, Jun Liang, Xiaoyan Lin, Deyun Luo, Rongsheng Zheng, Xin Wang, Guoping Sun, Liwei Wang, Leizhen Zheng, Hong Guo, Jingbo Wu, Nong Xu, Jianwei Yang, Honggang Zhang, Ying Cheng, Ningju Wang, Lei Chen, Zhining Fan, Piaoyang Sun, Hao Yu
Journal of Clinical Oncology. 20161,005 Citations
How much of the research on China Pharmaceutical University is open access?
ScholarIQopen access share
75%OPEN ACCESS
Gold
8%
Green
17%
Hybrid
0%
Bronze
50%
Closed
25%